Sunphenon

( DrugBank: - / KEGG DRUG: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	4

ID	Disease name (Link within this page)	Number of trials
113	Muscular dystrophy	2

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

trials per page:

Showing 1 to 4 of 4 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00799890 (ClinicalTrials.gov)	May 2009	28/11/2008	Sunphenon in Progressive Forms of Multiple Sclerosis	Monocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Eva ...	Multiple Sclerosis	Drug: Sunphenon EGCG;Drug: Placebo	Friedemann Paul	TAIYO EUROPE	Completed	18 Years	65 Years	All	61	Phase 2/Phase 3	Germany
2	NCT00525668 (ClinicalTrials.gov)	September 2007	4/9/2007	Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)	Sunphenon EGCg (Epigallocatechin-gallate) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)	Relapsing-remitting Multiple Sclerosis	Drug: epigallocatechin-gallate (Sunphenon);Drug: placebo	Charite University, Berlin, Germany	NULL	Completed	18 Years	60 Years	All	120	Phase 1/Phase 2	Germany
3	EUCTR2006-006323-39-DE (EUCTR)	19/06/2007	05/03/2007	Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MS	Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MS	relapsing-remitting multiple sclerosisICD classification: G35.1	Product Name: Sunphenon Other descriptive name: Sunphenon EGCg TM	Charité-Universitätsmedizin Berlin	NULL	Not Recruiting			Female: yes Male: yes	100		Germany
4	EUCTR2008-005213-22-DE (EUCTR)		22/08/2008	SUPREMES - Sunphenon in progressive forms of multiple sclerosis	SUPREMES - Sunphenon in progressive forms of multiple sclerosis - SUPREMES	primary and secondary progressive forms of multiple sclerosis;Therapeutic area: Diseases [C] - Nervo ...	Product Name: Sunphenon Other descriptive name: Sunphenon EGCg	Charite Universitätsmedizin Berlin	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2;Phase 3	Germany

First Previous1Next Last

113. Muscular dystrophy

Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01183767 (ClinicalTrials.gov)	December 30, 2010	17/8/2010	Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy	Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy	Duchenne Muscular Dystrophy	Drug: Epigallocatechin-Gallate;Drug: Placebo	Charite University, Berlin, Germany	NULL	Completed	5 Years	10 Years	All	33	Phase 2/Phase 3	Germany
2	EUCTR2009-016482-28-DE (EUCTR)	25/06/2010	15/03/2010	SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular Dystrophy	SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular Dystrophy - SUNIMUD	Duchenne Muscular Dystrophy;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Sunphenon EGCG INN or Proposed INN: Sunphenon	Charite Universitätsmedizin Berlin	NULL	Not Recruiting			Female: no Male: yes	40	Phase 2	Germany

First Previous1Next Last